Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
BUSINESS
Eisai Opts to Codevelop Biogen’s Aducanumab; New MS Copromotion Scheme Sealed
Eisai and Biogen are expanding their Alzheimer’s disease collaboration, with the Japanese major exercising its option to jointly develop and commercialize the US biotech’s investigational anti-amyloid beta (Aβ) antibody aducanumab, the two companies said on October 23. The Japanese pharma…
To read the full story
Related Article
- CMS Decision De-Facto Denial of All Medicare Patient Access to Aduhelm: Biogen
April 11, 2022
- Aduhelm Deal Revised, Eisai Poised to Sharpen Focus on Lecanemab: CEO
March 17, 2022
- Biogen/Eisai Alzheimer’s Pact Amended to Switch Aducanumab Collab to Royalty Scheme
March 16, 2022
- Expanded Aducanumab Collaboration Will Be a Plus for Other Alzheimer’s Pipelines: Eisai CEO
October 25, 2017
- Eisai, Biogen Idec to Jointly Develop, Commercialize AD Treatments
March 10, 2014
BUSINESS
- Espha Taps Korean Eylea Follow-On for First Biosimilar Foray
November 4, 2026
- Takara Bio, S-RACMO Finalize Cell Processing CDMO Transfer for January
November 4, 2026
- Roche Launches CDx for Takeda’s Elahere in Japan
November 4, 2026
- Santen’s Myopia Drug Bags Approval in South Korea
November 4, 2026
- Daiichi Sankyo H1 Revenue Zooms 20% as ADCs Drive Growth
November 2, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…